Literature DB >> 1277732

Clinical testing of the radiosensitiser Ro-07-0582. II. Radiosensitisation of normal and hypoxic skin.

S Dische, A J Gray, G D Zanelli.   

Abstract

The effectiveness of the radiosensitiser Ro-07-0582 has been tested in man by observing the skin reaction after irradiation using a radio-strontium source with and without administration of the drug. The skin reaction technique has been extended so that skin was irradiated when at low oxygen tension (hypoxic) as well as when fully oxygenated (oxic). Limbs have been made hypoxic by occlusion of the circulation using a sphygmomanometer cuff. To this has been added the prior use of an Esmarch's bandage to reduce the volume of blood in the skin and the enclosing of the limb in a bag of nitrogen. The Oxygen Enhancement Ratios obtained without the sensitiser in nine studies using this system ranged from 1-64 to 2-46. Using Ro-07-0582 skin reactions after oxic exposures were not enhanced but those after hypoxic exposures were markedly increased. The Relative Sensitising Efficiency expresses, as a percentage, the restoration of the sensitivity of cells protected by hypoxia. In six cases where Ro-07-0582 was given in doses ranging from 81 to 165 mg/kg, efficiencies ranged from 27 to 71%. These results can be compared with three studies using metronidazole where efficiencies ranged from 11 to 15%. Using comparable dosage Ro-07-0582 seems approximately three times more effective than metronidazole. In this first study in man, Ro-07-0582 appears to be a highly effective radiosensitiser of hypoxic cells.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1277732     DOI: 10.1016/s0009-9260(76)80138-9

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  9 in total

1.  Clinical experience with misonidazole.

Authors:  S Dische; M I Saunders
Journal:  Br J Cancer Suppl       Date:  1978-06

Review 2.  Clinical results of hypoxic cell radiosensitisation from hyperbaric oxygen to accelerated radiotherapy, carbogen and nicotinamide.

Authors:  M Saunders; S Dische
Journal:  Br J Cancer Suppl       Date:  1996-07

3.  A comparison of the effects of tumour growth delay of fractionated and single dose irradiation when administered with misonidazole (Ro-07-0582).

Authors:  E K Reddy
Journal:  Br J Cancer Suppl       Date:  1978-06

Review 4.  Assessing the bioreductive effectiveness of the nitroimidazole RSU1069 and its prodrug RB6145: with particular reference to in vivo methods of evaluation.

Authors:  J C Bremner
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

5.  Effect of hyperthermia on differential cytotoxicity of a hypoxic cell radiosensitizer, Ro-07-0582, on mammalian cells in vitro.

Authors:  I J Stratford; G E Adams
Journal:  Br J Cancer       Date:  1977-03       Impact factor: 7.640

6.  Clinical testing of the radiosensitizer Ro 07-0582: experience with multiple doses.

Authors:  S Dische; M I Saunders; M E Lee; G E Adams; I R Flockhart
Journal:  Br J Cancer       Date:  1977-05       Impact factor: 7.640

7.  Cytotoxicity of metronidazole (Flagyl) and misonidazole (Ro-07-0582): enhancement by lactate.

Authors:  J S Mahood; R L Willson
Journal:  Br J Cancer       Date:  1981-03       Impact factor: 7.640

8.  The quantitative response of human tumours to radiation and misonidazole.

Authors:  D V Ash; M J Peckham; G G Steel
Journal:  Br J Cancer       Date:  1979-12       Impact factor: 7.640

9.  Skin sensitization by misonidazole: a demonstration of uniform mild hypoxia.

Authors:  F A Stewart; J Denekamp; V S Randhawa
Journal:  Br J Cancer       Date:  1982-06       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.